Publisher
Springer Science and Business Media LLC
Subject
Drug Discovery,Pharmaceutical Science
Reference43 articles.
1. US Food and Drug Administration. What we do. 2018. https://www.fda.gov/about-fda/what-we-do. Accessed 14 Jun 2021.
2. US Food and Drug Administration. About Warning and Close-Out Letters. 2019. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/about-warning-and-close-out-letters. Accessed 10 Jun 2021.
3. US Food and Drug Administration. Regulatory Procedures Manual. Chapter 4 Advisory actions. 2022. https://www.fda.gov/media/71878/download. Accessed 10 Jun 2021.
4. Stewart KA, Neumann PJ. FDA actions against misleading or unsubstantiated economic and quality-of-life promotional claims: An analysis of warning letters and notices of violation. Value Heal. 2002;5(5):390–7.
5. Symonds T, Hackford C, Abraham L. A review of FDA warning letters and notices of violation issued for patient-reported outcomes promotional claims between 2006 and 2012. Value Heal. 2014;17(4):433–7.
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献